Following Lilly's proposed acquisition of Loxo, other possible takeover targets in the precision medicine field have emerged and Array, armed with more positive data on its colorectal cancer triplet, is near the top of the list.
Array at head of potential M&A target pack • Source: Shutterstock
The chances of Array Biopharma Inc. becoming the next M&A target for big pharma may have increased with more positive data from a late-stage trial of a triplet combination of its BRAF inhibitor Braftovi (encorafenib), MEK inhibitor Mektovi (binimetinib) and Eli Lilly & Co./
